Tag: marketing

HICKSVILLE, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- ChargeScape, a joint venture between BMW, Honda, Ford, and Nissan, today announced a partnership with PSEG Long Island to enroll electric vehicles (EVs) in the utility’s Peak Load Reduction program, a first in the nine-year history of the utility’s peak load reduction programs. Designed to alleviate strain on the power grid during summer months, the initiative will leverage ChargeScape’s AI-powered technology platform and aims to intelligently integrate more than 4,000 BMW EV drivers and 2,200 Ford EV drivers into the power grid. Participating customers will receive financial incentives for helping to support grid stability and community resilience through optimized EV charging.

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is complete and begins a standard review procedure, potentially supporting approval of the vaccine in the first half of 2026.

KØBENHAVN, Danmark, 22. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at de canadiske lægemiddelmyndigheder, Health Canada, har accepteret selskabets ansøgning om markedsføringstilladelse for den virus-lignende partikel (VLP)-baserede, enkelt-dosis chikungunyavaccinekandidat, CHIKV VLP, til forebyggelse af sygdom forårsaget af chikungunyavirus hos personer på 12 år og ældre. Dermed starter myndighedernes standardgennemgang, hvilket potentielt understøtter godkendelse af vaccinen i første halvår 2026.